Newly added drugs in national reimbursement drug list vs Clinical trial country use share in China
Newly added drugs in national reimbursement drug list and Clinical trial country use share in China, compared over time.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Newly added drugs in national reimbursement drug list
Unit: count · 2 observations
View the underlying data
| Period | Type | Value |
|---|---|---|
| as of 28 Nov 2024 | Actual | 91 |
| as of 7 Dec 2025 | Actual | 114 |
Clinical trial country use share
Unit: % · 3 observations
Provenance
Where these numbers come from
Newly added drugs in national reimbursement drug list
Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle.
2 observations in China · source organisations: NHSA, SCIO
Clinical trial country use share
Percentage of total clinical trial country uses accounted for by a given region.
3 observations in China · source organisations: IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring